User: Guest  Login
Title:

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

Document type:
Case Reports
Author(s):
Huemer, Florian; Melchardt, Thomas; Jansko, Bettina; Wahida, Adam; Jilg, Stefanie; Jost, Philipp J; Klieser, Eckhard; Steiger, Katja; Magnes, Teresa; Pleyer, Lisa; Greil-Ressler, Sigrun; Rass, Christof; Greil, Richard; Egle, Alexander
Abstract:
Acute myeloid leukemia (AML) is a disease of the elderly population and survival remains poor after failure of hypomethylating agents (HMA). The BCL-2 inhibitor venetoclax demonstrated activity as monotherapy and in combination with chemotherapy or HMA in AML. In this case series, patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA were treated with venetoclax within a named patient program at our tertiary cancer center in Salzburg, Austria. Between A...     »
Journal title abbreviation:
Eur J Haematol
Year:
2019
Journal volume:
102
Journal issue:
5
Pages contribution:
437-441
Language:
eng
Fulltext / DOI:
doi:10.1111/ejh.13218
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/30725494
Print-ISSN:
0902-4441
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Allgemeine Pathologie und Pathologische Anatomie
 BibTeX